Previous 10 |
Westbury Bancorp Inc (WBBW) is expected to report for quarter end 2023-06-30 Sumitomo Heavy Industries Ltd. ADR (SOHVY) is expected to report for Q1 2024 Belgravia Hartford Capital Inc (BLGVF) is expected to report for Q2 2023 Yasheng Group (HERB) is expected to report for Q2 2023 ...
Software AG ADR (STWRY) is expected to report for Q2 2023 Dai Nippon Printing Co Ltd ADR (DNPLY) is expected to report for quarter end 2023-06-30 Coffee Holding Co. Inc. (JVA) is expected to report for Q1 2024 Calloway`s Nursery, Inc. (CLWY) is expected to report for Q2 2023 Home ...
Sportsman's Warehouse Holdings Inc. (SPWH) is expected to report $0.02 for Q2 2024 Screen Holdings Co. Ltd. (DINRF) is expected to report for Q1 2024 Bionik Laboratories Corp (BNKL) is expected to report for Q1 2024 Atento S.A. (ATTOF) is expected to report for Q2 2023 Akoustis Te...
Skinvisible Inc (SKVI) is expected to report for Q1 2024
LAS VEGAS, NV / ACCESSWIRE / June 6, 2022 / Skinvisible, Inc. ("Skinvisible") (OTCQB:SKVI), is pleased to announce that its licensee Quoin Pharmaceuticals, Inc. ("Quoin") (NASDAQ:QNRX), has received U.S. FDA acceptance of its Investigational New Drug (IND) application for its licensed formul...
LAS VEGAS, NV / ACCESSWIRE / February 13, 2020 / Skinvisible, Inc. ("Skinvisible") (OTCQB:SKVI), is pleased to announce that it has signed a Licensing Agreement with Ovation Science Inc. for the exclusive worldwide rights to its DermSafe® hand sanitizer made with chlorhexidine gluconate...
LAS VEGAS, NV / ACCESSWIRE / October 22, 2019 / Skinvisible, Inc. ("Skinvisible") (OTCQB:SKVI), is pleased to announce that in conjunction with the mutual cancellation of the pending merger agreement with Quoin Pharmaceuticals, Inc. ("Quoin"), the parties have agreed to a product specific Li...
News, Short Squeeze, Breakout and More Instantly...
Results Demonstrate Significant Transdermal Performance of GLP-1 Receptor Agonists and CB-1 Receptor Antagonists Using Invisicare Technology LAS VEGAS, NV / ACCESSWIRE / July 11, 2024 / Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), (OTCQB: SKVI ), an innovative topical ...
Results Demonstrate Significant Transdermal Penetration of GLP-1 Receptor Agonists and CB-1 Receptor Antagonists Using Invisicare Technology LAS VEGAS, NV / ACCESSWIRE / July 9, 2024 / Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), (OTCQB: SKVI ), an innovative topical ...
Innovative Delivery System Shows Promise for GLP-1 Agonists, CB-1 Antagonists, and SGLT-2 Inhibitors LAS VEGAS, NV / ACCESSWIRE / June 24, 2024 / Skinvisible Pharmaceuticals, Inc. (OTCQB: SKVI ), an innovative topical / transdermal pharmaceutical research and development company, today anno...